VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 2065-2076

  Talagas, Matthieu ^a,b,c   Uguen, Arnaud ^c   Garlantezec, Ronan ^b   Fournier, Georges ^a,d   Doucet, Laurent ^c   Gobin, Eric ^c   Marcorelles, Pascale ^c   Volant, Alain ^c   De Braekeleer, Marc ^a,b,e  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^b CHU MORVAN   (France)

^c BREST UNIVERSITY HOSPITAL   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e INSERM   (France)

Author keywords

Angiogenesis; Immunohistochemistry; NRP1; Prostate cancer; Prostatectomy; Tissue array analysis; VEGFR1

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; NEUROPILIN 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ALPHA CHAIN; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CASE CONTROL STUDY; COMPARATIVE STUDY; DISTANT METASTASIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TUMOR CELL;

ANGIOGENESIS; IMMUNOHISTOCHEMISTRY; NRP1; PROSTATE CANCER; PROSTATECTOMY; TISSUE ARRAY ANALYSIS; VEGFR1;

AGED; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROPILIN-1; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84878167182     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR and Yarbro JW: Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 995-1000, 2000. (Pubitemid 30602040)
3. Roehl KA, Han M, Ramos CG, Antenor JA and Catalona WJ: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 172: 910-914, 2004. (Pubitemid 39096421)
4. Stearns ME and McGarvey T: Prostate cancer: Therapeutic, diagnostic, and basic studies. Lab Invest 67: 540-552, 1992.
5. Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI and Scardino PT: Critical review of prostate cancer predictive tools. Future Oncol 5: 1555-1584, 2009.
6. Carmeliet P: Angiogenesis in life, disease and medicine. Nature 438: 932-936, 2005.
7. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003. (Pubitemid 36749215)
8. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K and Eriksson U: Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 95: 11709-11714, 1998. (Pubitemid 28460479)
9. Park JE, Chen HH, Winer J, Houck KA and Ferrara N: Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to FLT- 1 but not to FLK-1/KDR. J Biol Chem 269: 25646-25654, 1994.
10. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC and Kreutzer DL: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54: 567-572, 1999. (Pubitemid 29407042)
11. Wang L, Zeng H, Wang P, Soker S and Mukhopadhyay D: Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem 278: 48848-48860, 2003.
12. Staton CA, Kumar I, Reed MW and Brown NJ: Neuropilins in physiological and pathological angiogenesis. J Pathol 212: 237-248, 2007. (Pubitemid 47010058)
13. Latil A, Bieche I, Pesche S, Valeri A, Fournier G, Cussenot O and Lidereau R: VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer 89: 167-171, 2000. (Pubitemid 30185926)
14. Shweiki D, Itin A, Soffer D and Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
15. Pugh CW and Ratcliffe PJ: Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 9: 677-684, 2003. (Pubitemid 36749216)
16. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964-3968, 1995.
17. Manders P, Beex LV, Tjan-Heijnen VC, Geurts-Moespot J, Van Tienoven TH, Foekens JA and Sweep CG: The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer 87: 772-778, 2002. (Pubitemid 35178755)
18. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De LM, De PS, Basolo F, Angeletti CA and Bevilacqua G: Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: A prospective study. J Natl Cancer Inst 89: 881-886, 1997. (Pubitemid 27268454)
19. Strohmeyer D, Rossing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G and Loening S: Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 45: 216-224, 2000.
20. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D and Parker C: Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 9: 342-351, 2008.
21. Peyromaure M, Camparo P, Badoual C, Descazeaud A and Dinh- Xuan AT: The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy. BJU Int 99: 1150-1153, 2007.
22. Peyromaure M, Badoual C, Camparo P, Grabar S, Goulvestre C, Fulla Y, Vieillefond A, Mao K and Dinh-Xuan AT: Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer. Oncol Rep 18: 145-149, 2007.
23. Mao K, Badoual C, Camparo P, Delongchamps NB, Vieillefond A, Dinh-Xuan AT and Peyromaure M: The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: A prospective evaluation in 100 patients undergoing radical prostatectomy. Can J Urol 15: 4257-4262, 2008.
24. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR and Harris AL: The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF1a, HIF2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 11: 7658-7663, 2005. (Pubitemid 41611607)
25. Jans J, van Dijk JH, van SS, van der Groep P, Willems SH, Jonges TN, van Diest PJ and Bosch JL: Expression and localization of hypoxia proteins in prostate cancer: Prognostic implications after radical prostatectomy. Urology 75: 786-792, 2010.
26. Mao K, Camparo P, Badoual C, Peyromaure M, Delongchamps NB, Vieillefond A and Dinh-Xuan AT: The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy. Oncol Rep 19: 171-175, 2008. (Pubitemid 351176146)
27. Yacoub M, Coulon A, Celhay O, Irani J, Cussenot O and Fromont G: Differential expression of the semaphorin 3A pathway in prostatic cancer. Histopathology 55: 392-398, 2009.
28. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
29. Sobin LH, Gospodarowicz MK, and Wittekind C: TNM Classification of Malignant Tumours. Chichester, West Sussex, UK, Wiley-Blackwell, 2010.
30. Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, Teillac P and Tunn UW: Management of prostate-specific antigen relapse in prostate cancer: A European Consensus. Int J Clin Pract 58: 382-390, 2004. (Pubitemid 38714445)
31. Jhaveri FM and Klein EA: How to explore the patient with a rising PSA after radical prostatectomy: Defining local versus systemic failure. Semin Urol Oncol 17: 130-134, 1999. (Pubitemid 29380639)
32. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD and Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597, 1999. (Pubitemid 29211767)
33. D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen MH, Hurwitz M, Kantoff PW, Tomaszewski JE, Renshaw AA, Wein A and Richie JP: Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol 18: 3240-3246, 2000.
34. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F and Heidenreich A: EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Actas Urol Esp 35: 565-579, 2011 (in Spanish).
35. Fujita K, Nakayama M, Nakai Y, Takayama H, Nishimura K, Ujike T, Nishimura K, Aozasa K, Okuyama A and Nonomura N: Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy. Cancer Sci 100: 1047-1050, 2009.
36. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF and Detmar M: VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201: 1089-1099, 2005. (Pubitemid 40524677)
37. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D'Amore PA, Dana MR, Wiegand SJ and Streilein JW: VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 113: 1040-1050, 2004. (Pubitemid 38544126)
38. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De MM, Autiero M, Wyns S, Plaisance S, Moons L, van RN, Giacca M, Stassen JM, Dewerchin M, Collen D and Carmeliet P: Anti- PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475, 2007.
39. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW and Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167: 528-534, 2002. (Pubitemid 34074521)
40. Dales JP, Garcia S, Bonnier P, Duffaud F, Carpentier S, Djemli A, Ramuz O, Andrac L, Lavaut M, Allasia C and Charpin C: Prognostic significance of VEGF receptors, VEGFR-1 (FLT-1) and VEGFR-2 (KDR/FLK-1) in breast carcinoma. Ann Pathol 23: 297-305, 2003 (in French). (Pubitemid 37279899)
41. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De MM, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van HP, Dehio C, Hicklin DJ, Persico G, Herbert JM, Communi D, Shibuya M, Collen D, Conway EM and Carmeliet P: Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors FLT1 and FLK1. Nat Med 9: 936-943, 2003. (Pubitemid 36889938)
42. Sawano A, Takahashi T, Yamaguchi S and Shibuya M: The phosphorylated 1169-tyrosine containing region of FLT-1 kinase (VEGFR-1) is a major binding site for PLCγ. Biochem Biophys Res Commun 238: 487-491, 1997. (Pubitemid 27464413)
43. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De MM, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D and Persico MG: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583, 2001. (Pubitemid 32448325)
44. Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, Carmeliet P and Young PP: VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 20: 1495-1497, 2006.
45. Adini A, Kornaga T, Firoozbakht F and Benjamin LE: Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 62: 2749-2752, 2002. (Pubitemid 34525755)
46. Rafii S, Meeus S, Dias S, Hattori K, Heissig B, Shmelkov S, Rafii D and Lyden D: Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol 13: 61-67, 2002. (Pubitemid 35418315)
47. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R and Rafii S: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201, 2001. (Pubitemid 33063774)
48. Matsumoto K, Suzuki K, Koike H, Hasumi M, Matsui H, Okugi H, Shibata Y, Ito K and Yamanaka H: Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia. Anticancer Res 23: 3767-3773, 2003. (Pubitemid 37474323)
49. Cao Y: Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2: re1, 2009.
50. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM and Shibuya M: MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lungspecific metastasis. Cancer Cell 2: 289-300, 2002. (Pubitemid 41043963)
51. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S and Lyden D: VEGFR1- positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827, 2005. (Pubitemid 41753060)
52. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA and Klagsbrun M: Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 146: 233-242, 1999.
53. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK and Riddick AC: The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 105: 8-13, 2010.
54. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH and Eckardt KU: Widespread hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs. FASEB J 17: 271- 273, 2003.
55. Simon MP and Pouysségur J: Hypoxie et signalisation angiogénique. In: Angiogenèse. Paris, France, John Libbey Eurotext/AMGEN Oncologie, pp. 34-47, 2009.